Our team works at the intersection of many fields of science. We use cell biology to improve targeted therapy and immunotherapy against cancer. Our research focuses on the temporary inhibition of endocytosis to improve responses to monoclonal antibody therapies and reversal of this inhibition to improve toxin payload delivery to tumours. We are also the scientific leads of clinical trials of combination therapy approaches we have discovered and work closely with surgeons, oncologists, pathologists, radiologists, medicinal chemists, nuclear medicine professional and pharmacologists to translate basic scientific findings to better outcomes for cancer patients.

PhD and Master students

  • Mr Benedict Lum (PhD student)
  • Dr Caroline Cooper (Staff Pathologist PAH and MPhil student)
  • Dr Emma Karlsen (General Surgery PHO and PhD student)
  • Dr James Nightingale (Ear, Nose and Throat Surgery PHO and PhD student)
  • Mr Jason Lee (PhD student)
  • Dr Joan Sia Tan Tefay (General Surgery PHO and MPhil student)
  • The ins and outs of endocytosis inhibition: providing diverse opportunities for treatment of incurable cancers.

  • Therapeutic targets and immune therapy for head and neck adenoid cystic carcinoma.

  • Open-label Phase II study investigating the efficacy of Cetuximab and prochlorperazine (Stemetil) combination therapy in patients with metastatic Head and Neck Carcinoma (CESTEM II study).

  • HER2Stem: Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study.

  • Solving surgical and therapeutic issues in the treatment of Pancreatic ductal adenocarcinoma (PDAC).

  • Novel Biomarkers and Treatment Approaches in Breast Cancer.

  • Analysis of markers of progression and recurrence in breast cancer.

  • Combination therapies to improve delivery of PSMA-targeted therapies.

  • Novel therapeutic strategies for treatment of cutaneous SCCHN with perineural invasion.

  • Characterising the protein complexes responsible for immune synapse formation to allow rational drug design to modulate immunity both as increase and decrease.

Partner organisations/institutions/supporters/collaborators

  • Adenoid Cystic Carcinoma Research Foundation
  • Allied Leisure and Health (via PARF)
  • Aveo (via PARF)
  • Cancer Council Queensland
  • Children’s Medical Research Institute (CMRI, Sydney)
  • EO (Entrepreneurs Organisation)
  • Garvan Institute of Medical Research
  • Merchant Foundation
  • Merck KGaA
  • Memorial Sloan Kettering Cancer Center
  • Metro South Health
  • National Breast Cancer Foundation
  • Petter McCallum Cancer Centre
  • Princess Alexandra Research Foundation
  • Queensland Head and Neck Cancer Centre
  • Rotary International (Nundah)
  • Telix Pharmaceuticals
  • University of Newcastle
  • University of Sydney

To donate to cancer therapy research, click on the button below.